29. A ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a genomic gene corresponding to SEQ ID NO:1 or SEQ ID NO:2 wherein said catalytic domain is capable of cleaving said target mRNA sequence to reduce or inhibit IGF-1 mediated cell proliferation or inflammation.

30. A nucleic acid molecule comprising at least about 10 nucleotides that hybridizes to or forms a heteroduplex with an mRNA molecule directed from a gene corresponding to a genomic form of SEQ ID NO:1 or SEQ ID NO:2 and which thereby reduces translation of said mRNA molecule.

31. A nucleic molecule according to Claim 30 wherein said molecule comprises at least about 15 nucleotides.

32. A nucleic acid molecule according to Claim 31 wherein said molecule hybridizes to or forms a heteroduplex with at least one nucleotide sequence of about 15 nucleotides in length present as a contiguous sequence within SEQ ID NO:1 or SEQ. ID NO:2.

33. A pharmaceutical composition for topical administration said composition comprising a nucleic acid molecule that inhibits or otherwise reduces IGF-1 mediated cell proliferation wherein said nucleic acid comprises at least about ten nucleotides and hybridizes to or forms a heteroduplex with an mRNA molecule directed from a gene encoding human IGFBP-

2 or IGFBP-3, said composition further comprising one or more pharmaceutically acceptable carriers.

36. A pharmaceutical composition according to Claim 33 wherein said antisense molecule hybridizes to or forms a duplex with at least one nucleotide sequence of about 15 nucleotides in length present as a contiguous sequence within SEQ ID NO:2.